
Is cancer care really over?
Why RGCC CTC Testing May Reveal the Hidden Risks Still Lurking in Your Body
For many people, the end of cancer treatment marks the end of their journey—often celebrated as a full recovery. But the truth is, cancer doesn’t always end when chemotherapy, surgery, or radiation do. Research increasingly shows that small numbers of cancer cells may remain dormant in the body, quietly waiting for the right moment to resurface. This is why, even years after completing treatment, patients can still face recurrence or metastasis.
So how can we detect these “invisible threats” that evade standard tests? This is exactly where RGCC CTC (Circulating Tumor Cell) testing comes in—a cutting-edge tool designed to identify residual cancer activity before it becomes a visible problem.